No Data
No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Zhejiang Jingxin Pharmaceutical (002020.SZ) has repurchased a total of 3.01% of its shares, costing 0.32 billion yuan.
Zhejiang Jingxin Pharmaceutical (002020.SZ) announced that as of February 28, 2025, the company will repurchase shares...
Zhejiang Jingxin Pharmaceutical (002020.SZ): The company has not yet made any plans for gene therapy.
On February 18, Glonghui reported that Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform that the company currently does not have any plans for gene therapy.
Zhejiang Jingxin Pharmaceutical Co., Ltd. (SZSE:002020) Looks Inexpensive But Perhaps Not Attractive Enough
Zhejiang Jingxin Pharmaceutical (002020.SZ) has spent 0.124 billion yuan to repurchase 1.17% of its shares.
Zhejiang Jingxin Pharmaceutical (002020.SZ) issued an announcement that as of January 31, 2025, the company will continue its share repurchase...
Express News | Zhejiang Jingxin Pharmaceutical Says to Buy Back up to 400 Mln Yuan Worth of Shares in 12 Months